Bafnapharm Profit & Loss Annual

BSE: 532989 | NSE: BAFNAPH | ISIN: INE878I01022 | Sector: Biotechnology & Drugs

81.74 +1.74 (2.18%)Updated : 25 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	152.47	115.45	85.14	71.22
Total Revenue	152.47	115.45	85.14	71.22
Costof Revenue Total	106.91	76.59	51.28	45.46
Gross Profit	45.56	38.85	33.86	25.76
Selling/ General/ Admin Expenses Total	19.03	15.87	14.65	11.98
Depreciation/ Amortization	5.00	5.33	5.49	4.48
Unusual Expense( Income)	0.00	0.00	2.16	-
Other Operating Expenses Total	15.43	5.72	7.25	3.48
Total Operating Expense	146.36	103.51	80.83	65.40
Operating Income	6.11	11.94	4.31	5.82
Interest Inc( Exp) Net- Non- Op Total	-22.90	-2.76	-7.94	0.00
Other Net	3.53	-0.24	1.70	0.01
Net Income Before Taxes	7.35	11.62	5.22	5.83
Provisionfor Income Taxes	0.00	0.28	0.00	0.00
Net Income After Taxes	7.35	11.34	5.22	5.83
Net Income Before Extra Items	7.35	11.34	5.22	5.83
Net Income	7.35	11.34	5.22	5.83
Income Availableto Com Excl Extra Ord	7.35	11.34	5.22	5.83
Income Availableto Com Incl Extra Ord	7.35	11.34	5.22	5.83
Diluted Net Income	7.35	11.34	5.22	5.83
Diluted Weighted Average Shares	2.36	2.33	2.38	2.37
Diluted EPS Excluding Extra Ord Items	3.11	4.86	2.19	2.46
Diluted Normalized EPS	3.11	4.78	3.10	2.46
Gain( Loss)on Saleof Assets	-	1.96	-	-